TY - JOUR T1 - C-reactive Protein is a Potential Prognostic Factor for Metastatic Gastric Cancer JF - Anticancer Research JO - Anticancer Res SP - 491 LP - 496 VL - 32 IS - 2 AU - TAKAYA SHIMURA AU - MIKA KITAGAWA AU - TOMONORI YAMADA AU - MASAHIDE EBI AU - TSUTOMU MIZOSHITA AU - SATOSHI TANIDA AU - HIROMI KATAOKA AU - TAKESHI KAMIYA AU - TAKASHI JOH Y1 - 2012/02/01 UR - http://ar.iiarjournals.org/content/32/2/491.abstract N2 - Background/Aim: C-reactive protein (CRP) has been associated with the development of many carcinomas, but the significance of CRP remains unclear for metastatic gastric cancer (MGC). Patients and Methods: Sixty one patients who received S-1 plus cisplatin for MGC were retrospectively identified and categorized into two groups depending on the serum CRP level before chemotherapy. Results: Overall survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 292 days versus 451 days; p=0.0004). Moreover, progression-free survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 115 days versus 188 days; p=0.0010). In a multivariate analysis, serum CRP level before chemotherapy was an independent prognostic factor for MGC (hazard ratio 4.20 [95% CI, 1.66 to 10.64] p=0.002). Conclusion: Serum CRP level before chemotherapy might be a potential prognostic factor for MGC. ER -